HLS Therapeutics Inc.
TSX:HLS.TO
Overview | Financials
Company Name | HLS Therapeutics Inc. |
Symbol | HLS.TO |
Currency | CAD |
Price | 3.37 |
Market Cap | 107,142,410 |
Dividend Yield | 0% |
52-week-range | 3 - 5.48 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Craig Stuart Millian M.B.A. |
Website | https://www.hlstherapeutics.com |
An error occurred while fetching data.
About HLS Therapeutics Inc.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD